OBJECTIVE: Fluid therapy is a cornerstone of the early treatment of acute pancreatitis (AP), but data are conflicting on whether it affects disease severity. Administering greater fluid volumes (FVs) during induction of experimental AP preserves pancreatic perfusion and reduces severity but does not prevent onset of AP. We hypothesized that administering larger FV during endoscopic retrograde cholangiopancreatography (ERCP) associates with less severe post-ERCP pancreatitis (PEP). METHODS: In a retrospective cohort study, we identified 6505 patients who underwent 8264 ERCPs between January 1997 and March 2009; 211 of these patients developed PEP (48 mild, 141 moderate, and 22 severe). Data for FVs were available for 173 patients with PEP. RESULTS: In univariable analysis, only 1 of 16 variables was significantly associated with moderate to severe PEP--larger periprocedural FV was protective (0.94 T 0.3 L vs 0.81 T 0.4 L; P = 0.0129). Similarly,multivariable analysis of moderate to severe PEP identified 1 independent predictor-- larger periprocedural FV was protective (odds ratio, 0.20; 95% confidence interval, 0.05-0.83). Conversely, moderate to severe disease correlated with larger FV administered after PEP diagnosis(reflecting treatment decisions). CONCLUSIONS: This hypothesis-generating study suggests that administering larger periprocedural FVs is protective against moderate to severe PEP. Prospective studies on this topic are warranted.
OBJECTIVE: Fluid therapy is a cornerstone of the early treatment of acute pancreatitis (AP), but data are conflicting on whether it affects disease severity. Administering greater fluid volumes (FVs) during induction of experimental AP preserves pancreatic perfusion and reduces severity but does not prevent onset of AP. We hypothesized that administering larger FV during endoscopic retrograde cholangiopancreatography (ERCP) associates with less severe post-ERCP pancreatitis (PEP). METHODS: In a retrospective cohort study, we identified 6505 patients who underwent 8264 ERCPs between January 1997 and March 2009; 211 of these patients developed PEP (48 mild, 141 moderate, and 22 severe). Data for FVs were available for 173 patients with PEP. RESULTS: In univariable analysis, only 1 of 16 variables was significantly associated with moderate to severe PEP--larger periprocedural FV was protective (0.94 T 0.3 L vs 0.81 T 0.4 L; P = 0.0129). Similarly,multivariable analysis of moderate to severe PEP identified 1 independent predictor-- larger periprocedural FV was protective (odds ratio, 0.20; 95% confidence interval, 0.05-0.83). Conversely, moderate to severe disease correlated with larger FV administered after PEP diagnosis(reflecting treatment decisions). CONCLUSIONS: This hypothesis-generating study suggests that administering larger periprocedural FVs is protective against moderate to severe PEP. Prospective studies on this topic are warranted.
Authors: Tim Strate; Oliver Mann; Helge Kleinhans; Skelkim Rusani; Claus Schneider; Emre Yekebas; Marc Freitag; Thomas Standl; Christian Bloechle; Jakob R Izbicki Journal: Pancreas Date: 2005-04 Impact factor: 3.327
Authors: Abhishek Choudhary; Matthew L Bechtold; Murtaza Arif; Nicholas M Szary; Srinivas R Puli; Mohamed O Othman; Wilson P Pais; Mainor R Antillon; Praveen K Roy Journal: Gastrointest Endosc Date: 2011-02 Impact factor: 9.427
Authors: Chi-Liang Cheng; Stuart Sherman; James L Watkins; Jeffrey Barnett; Martin Freeman; Joseph Geenen; Michael Ryan; Harrison Parker; James T Frakes; Evan L Fogel; William B Silverman; Kulwinder S Dua; Giuseppe Aliperti; Paul Yakshe; Michael Uzer; Whitney Jones; John Goff; Laura Lazzell-Pannell; Abdullah Rashdan; M'hamed Temkit; Glen A Lehman Journal: Am J Gastroenterol Date: 2006-01 Impact factor: 10.864
Authors: J Schmidt; K Huch; K Mithöfer; H G Hotz; H P Sinn; H J Buhr; A L Warshaw; C Herfarth; E Klar Journal: Intensive Care Med Date: 1996-11 Impact factor: 17.440
Authors: Tim Strate; Oliver Mann; Helge Kleinhans; Claus Schneider; Wolfram T Knoefel; Emre Yekebas; Thomas Standl; Christian Bloechle; Jakob R Izbicki Journal: Ann Surg Date: 2003-11 Impact factor: 12.969
Authors: B Joseph Elmunzer; Jose Serrano; Amitabh Chak; Steven A Edmundowicz; Georgios I Papachristou; James M Scheiman; Vikesh K Singh; Shyam Varadurajulu; John J Vargo; Field F Willingham; Todd H Baron; Gregory A Coté; Joseph Romagnuolo; April Wood-Williams; Emily K Depue; Rebecca L Spitzer; Cathie Spino; Lydia D Foster; Valerie Durkalski Journal: Trials Date: 2016-03-03 Impact factor: 2.279
Authors: Rupjyoti Talukdar; Ayesha Kamal; Venkata S Akshintala; Rajesh Goud; Sundeep Lakhtakia; Mohan K Ramchandani; Manu Tandan; G V Rao; Zaheer Nabi; Rajesh Gupta; Rakesh Kalapala; Jahangeer Basha; Manohar Reddy; Vijay K Rai; Mahesh K Goenka; Saroj Sinha; Rakesh Kochhar; B Joseph Elmunzer; Mouen A Khashab; Anthony N Kalloo; Vikesh K Singh; D Nageshwar Reddy Journal: Endosc Int Open Date: 2020-06-16